Search
October 27, 2022

Association of mRNA Vaccination with Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers

Authors

Lauren E.W. Olsho, Meredith G. Wesley, Tyler C. Morrill, Meghan H. Herring, Deanna E. Fleary, Abt Global Inc.; Mark G. Thompson, Lauren Grant, Josephine Mak, Ashley L. Fowlkes, Young M. Yoo, John T. Jones, Monica Dickerson, Julie Mayo Lamberte, Centers for Disease Control and Prevention; Sarah K. Yoon, Andrew L. Phillips, Kurt T. Hegmann, Matthew S. Thiese, Matthew Brunner, Jenna Praggastis, University of Utah Health; Allison L. Naleway, Holly C. Groom, Jennifer L. Kuntz, Kaiser Permanente Northwest Center for Health Research; Jennifer Meece, Elisha Stefanski, Adam Bissonnette, Marshfield Clinic Research Institute; Thomas P. Fabrizio, Richard J. Webby, St Jude Children's Research Hospital; Alberto J. Caban-Martinez, Natasha Schaefer Solle, University of Miami; Jefferey L. Burgess, Katherine Ellingson, James Hollister, Edward J. Bedrick, James Romine, Sana M. Khan, Shawn Beitel, University of Arizona; Manjusha Gaglani, Kayan Dunnigan, Spencer Rose, Baylor Scott and White Health; Manjusha Gaglani, Texas A&M University College of Medicine; Allen Bateman, Kyley Guenther, Wisconsin State Laboratory of Hygiene; Jessica Lundgren, Angela Hunt, Karley Respet, Harmony L. Tyner, St Luke’s Regional Health Care System; Karen Lutrick, Patrick Rivers, University of Arizona; Marilyn J. Odean, St Luke’s, Duluth, Minnesota

A study of essential and frontline workers with COVID-19 showed that two or three mRNA vaccine doses reduced severity of COVID-19 symptoms. The study in the Journal of the American Medical Association found that recent vaccinations reduced fever and chills, hours of work missed, the need for medical care, and the amount of virus in the nose (viral load) compared with those who were unvaccinated.

The study for the Centers for Disease Control and Prevention (CDC), conducted by a team that included Abt Global researchers, involved 1,199 participants from six U.S. states who collected nasal specimens weekly--regardless of symptoms and at the onset of symptoms—from December 14, 2020, to April 19, 2022, and tested positive for COVID-19 infection. The study found that two or three vaccine doses less than 150 days before a Delta infection and three doses before an Omicron infection were significantly associated with milder COVID-19 symptoms, while two doses before either variant were significantly associated with a lower viral load.

The study confirmed substantial differences between Delta and Omicron. While only 3.9 percent of Delta infections were asymptomatic, 20.2 percent of Omicron infections were. If people didn’t know they had Omicron, they could have been unwitting spreaders and contributed to Omicron’s higher transmission rate.

The report noted that the precision and statistical significance of some estimates varied and could have been affected by “confounders,” that is, non-medical factors.  For example, different employer isolation protocols could affect the number of work hours missed. In addition, those who are vaccinated may be more likely to report symptoms than those who aren’t vaccinated. The findings suggest that staying up to date with COVID-19 vaccinations and boosters can help keep people from getting seriously ill.


Read More

COVID-19 in North America

Healthy Military Families Undergird National Readiness

The only DoW-wide longitudinal study on U.S. military family health has generated vital evidence to inform programs, policies, and support services critical to family stability and force readiness.

Learn More
Impact Brief

Closing the Gap: Surveying LA Renters to Improve Housing Access

Abt helped HACLA collect and analyze current Los Angeles rental data, showing rents were about 12% higher than federal estimates and providing evidence to support voucher subsidy levels that better reflect local housing costs and improve access to stable housing.

Learn More
Impact Brief

Regulating Harmful Contaminants for Healthier Communities

Abt supported the EPA in developing and implementing data-driven regulations for hazardous chemicals—particularly carbon tetrachloride—helping turn scientific evidence into enforceable protections that reduce risks to workers, nearby communities, and the environment.

Learn More
Impact Brief

From Exposure to Protection: Securing Safe Drinking Water

Abt helped the EPA develop data-driven regulations, treatment tools, and exposure models that strengthen protections against contaminants such as PFAS and lead, improving drinking water safety for millions of Americans.

Learn More
Impact Brief